BridgeBio (BBIO) Q3 2025 earnings summary

Executive summary

• Net product revenue reached $216.4 million for the nine months ended September 30, 2025, driven by the commercial launch of Attruby in the U.S. and Beyonttra in the EU and Japan, with Q3 2025 revenue at $120.7 million and strong market share expansion.

• Positive Phase 3 results for BBP-418 (LGMD2i/R9) and encaleret (ADH1), both meeting all primary and secondary endpoints, with plans for NDA filings in the first half of 2026.

• Robust financial position with $645.9 million in cash, cash equivalents, and marketable securities at quarter end, supporting commercialization and pipeline advancement.

• Major financing activities included a $575 million convertible note issuance, $300 million royalty sale, and $48.3 million in stock repurchases.

• Significant licensing agreements with Bayer and Kyowa Kirin contributed to $105 million in milestone revenue.

Financial highlights

• Q3 2025 total revenue was $120.7 million, up from $2.7 million in Q3 2024, and nine-month 2025 revenue was $347.9 million, up $131.9 million year-over-year, mainly due to Attruby's launch.

• Net product revenue was $216.4 million for the nine months, with $108.1 million in Q3 2025; royalty revenue was $6.1 million for the nine months.

• Operating expenses increased to $265.9 million in Q3 2025, with SG&A reflecting commercial launch investments.

• Net loss attributable to common stockholders was $182.7 million for Q3 2025 ($0.95 per share), and $532.1 million for the nine months.

• Cash, cash equivalents, and marketable securities totaled $645.9 million as of September 30, 2025.

Outlook and guidance

• NDA filings for BBP-418 and encaleret planned for the first half of 2026, with topline results for infigratinib in achondroplasia expected in early 2026.

• Management expects future revenue growth from recurring product sales and royalties, with cash runway projected to fund operations for at least the next 12 months.

• Ongoing restructuring and cost-saving initiatives are expected to reduce operating expenses.